Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Uterine Cervical Neoplasms 2Solid Tumors 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Advanced Malignant Solid Neoplasm 2Vaginal Neoplasms 1Triple-negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma 1Previously Treated Non Small Cell Lung Cancer 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Pinealoma 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Metastatic Pancreatic Adenocarcinoma 1Meningeal Carcinomatosis 1Medulloblastoma 1Lymphoid Interstitial Pneumonia 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1

Interventions

Gemcitabine 5Paclitaxel 4Nivolumab 3cobimetinib 2atezolizumab 2adavosertib 2Ramucirumab 2N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 2Carboplatin 2zansecimab 1tocilizumab 1tivozanib 1tislelizumab 1temsirolimus 1ridaforolimus 1plocabulin 1pexidartinib 1pevonedistat 1pembrolizumab 1pamiparib 1obinutuzumab 1necitumumab 1liposomal doxorubicin 1lenvatinib 1glasdegib 1futuximab 1demplatin pegraglumer 1birinapant 1avelumab 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Solid Tumors × adavosertib × Clear all
NCT00648648 2023-09-21

MK-1775-001

Merck Sharp & Dohme LLC

Phase 1 Completed
206 enrolled 40 charts
Other solid neoplasm

Solid Tumors

NCT01748825 2021-07-26

AZD1775 for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
67 enrolled 24 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡